GLP-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution By Donnisa Edmonds, C2ST Intern, University of Chicago In 2021, the FDA announced that they had approved Wegovy, a GLP-1 receptor agonist, as a treatment for chronic weight management
Stringy mucus in or around the eyes
Diala Alatassi, MD, FACP Medical Reviewer Diala Alatassi, MD, is a board-certified obesity medicine specialist who is committed to providing comprehensive, compassionate, and personalized care
Bring a detailed record that includes: Pre-existing conditions such as diabetes, hypertension, PCOS Family medical history detailing obesity, metabolic disorders, and endocrine conditions Current medications including prescriptions, supplements, and over-the-counter drugs Previous surgeries or procedures, particularly those related to weight loss or digestion (e.g., bariatric surgery) Before your visit, familiarize yourself with GLP-1 medications like Wegovy, Ozempic, Zepbound, and Mounjaro
If your employer has announced a GLP-1 coverage change that takes effect in the coming weeks or months, now is the time to act not after youve missed your first dose and your next refill isnt covered
